(Q41997352)

English

A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients

scientific article published on 4 September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients (English)

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

7

object named as

Guy Storme

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

author name string

Darius Norkus

1

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Agata Karklelyte

2

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Benedikt Engels

3

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Harijati Versmessen

4

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Romas Griskevicius

5

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Mark De Ridder

6

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Eduardas Aleknavicius

8

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Ernestas Janulionis

9

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Konstantinas Povilas Valuckas

10

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

4 September 2013

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Radiation Oncology

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

8

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

206

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

https://scigraph.springernature.com/pub.10.1186/1748-717x-8-206

0 references

Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

5 June 2018

Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

5 June 2018

Quality-of-life outcomes in high-risk prostate cancer patients treated with helical tomotherapy in a hypofractionated radiation schedule with long-term androgen suppression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

5 June 2018

Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

5 June 2018

RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

5 June 2018

What dose of external-beam radiation is high enough for prostate cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

5 June 2018

Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

5 June 2018

Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

18 August 2018

Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

18 August 2018

A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

18 August 2018

Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

18 August 2018

Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

18 August 2018

Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

18 August 2018

Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

18 August 2018

Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

18 August 2018

Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3846611

18 August 2018

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial

1 reference

https://api.crossref.org/works/10.1186%2F1748-717X-8-206

21 January 2018

Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/24007322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24007322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Don't squeeze hypofractionated schedules into too-short overall times

1 reference

https://pubmed.ncbi.nlm.nih.gov/24007322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area

1 reference

https://pubmed.ncbi.nlm.nih.gov/24007322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ultra-High Dose (86.4 Gy) IMRT for Localized Prostate Cancer: Toxicity and Biochemical Outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24007322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/24007322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life and satisfaction with outcome among prostate-cancer survivors

1 reference

https://pubmed.ncbi.nlm.nih.gov/24007322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24007322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute and Late Toxicity in a Randomized Trial of Conventional Versus Hypofractionated Three-Dimensional Conformal Radiotherapy for Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24007322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1748-717X-8-206

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41997352&oldid=1931581596"